• BioInvent’s 2025 annual report outlined a strategic shift toward BI-1808 and BI-1206, prioritizing its most advanced clinical assets.
• Development of earlier-stage candidates BI-1910 and BI-1607 was paused, reducing company-run clinical programs from six to four.
• BI-1808 monotherapy achieved a 46% objective response rate in evaluable patients with relapsed or refractory cutaneous T-cell lymphoma.
• The BI-1206 combination with rituximab and acalabrutinib maintained an 80% objective response rate among 20 evaluable patients in February 2026.
• Additional funding came from selling future mezagitamab royalty and milestone rights to XOMA Royalty.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.